ISRCTN36210045已完成不适用
Radioimmunotherapy with 90Y Ibritumumab Tiuxetan in B-cell CD20+ indolent non-Hodgkin Lymphoma: A retrospective study
Foundation for the Study of hematology in Aragon [Fundación para el Estudio de la Hematologia y Hemoterapia en Aragón](FEHHA)0 个研究点目标入组 50 人开始时间: 2013年4月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adults patients with an excisional biopsy-confirmed diagnosis of CD20+ F-NHL grade 1, 2, or 3a according to the revised WHO classification system
- •2. ECOG performance status = 2
- •3. Absolute neutrophil count (ANC) = 1,500/µL
- •4. Absolute platelet count (APC) = 100,000/µL
- •5. Bone marrow total lymphocytes = 25% by morphological counting
- •6. Serum bilirubin = 2.0mg/dL and serum creatinine = 2.0mg/dL
- •7. All patients were requested to sign an informed consent form
排除标准
- •1. Presence of any other malignancy or history of prior malignancy within 5 years of study entry. This does not apply to-non melanoma skin tumors and in situ cervical cancer.
- •2. Prior radioimmunotherapy
- •3. Presence of primary central nervous system (CNS) lymphoma at first diagnosis
- •4. Known seropositivity for hepatitis C virus (HCV) or hepatitis B surface antigen (HbsAg).
- •5. Known history of HIV infection
- •6. Abnormal liver function: total bilirubin > 2 × ULN unless secondary to Gilbert disease.
- •7. Abnormal renal function: serum creatinine > 2.0 × ULN
- •8. Ongoing toxic effects of chemotherapy > grade 2 and expected to interfere with Zevalin® treatment.
研究者
相似试验
已完成
不适用
Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCTRefractory B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaNCT02992223A.O.U. Città della Salute e della Scienza58
已完成
1 期
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaStage III Adult Burkitt LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaWaldenström MacroglobulinemiaPost-transplant Lymphoproliferative DisorderNCT00064246National Cancer Institute (NCI)28
已完成
3 期
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line ChemotherapyLymphoma, Non-HodgkinNCT00185393Bayer414
终止
1 期
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory LymphomaAIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS LymphomaRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaPost-transplant Lymphoproliferative DisorderNCT00036855National Cancer Institute (NCI)36
进行中（未招募）
1 期
Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma. - ZEUSEUCTR2006-006808-11-ITAZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA